

30 September - 3 October, 2025 | Athens, Greece

www.bioemtech.com



BIOEMTECH

5th Annual

BPW


BIOEMTECH's Preclinical Workshop

Once per year, in BIOEMTECH Laboratories, we open our doors and meet with the Drug Discovery & Targeted Radioligand Therapy community, to discuss methodologies & share experience & knowledge. We welcome renowned speakers from Academia & Industry and explore optimal procedures, in our boutique GLP laboratories.



BPW's 2025 Partners:





Welcome to the 5th Preclinical Models Imaging Workshop!

After more than 15 years of active involvement in the field of **Drug and Radioligand Therapy**, we decided to create the kind of workshop we wish had existed during our own journey. Drawing on our experience as engaged participants in numerous scientific events, our aim is to offer **a truly unique meeting for knowledge exchange and networking**. One that equips participants with **a deep understanding of the most pressing and cutting-edge topics in the field**, while also fostering meaningful **new collaborations and professional connections**.

Main workshop points:

- Oncology Therapies: Exploring combination strategies and optimal therapeutic schemes
- Preclinical Tools: In vivo models, choice of isotopes, and approaches to dosimetry
- Bridging Preclinical and Clinical Research: Translational challenges and opportunities
- Vectors in Preclinical RLT: Target selection and probe development
- The Business of Radioligand Therapy (RLT): From early-stage development to market considerations
- Artificial Intelligence in RLT: Emerging tools and applications across the development pipeline

Hands-On session on:

- Radiochemistry model preparation, *in vivo* imaging and post-processing

Looking forward to welcoming you in Athens and sharing insightful conversations!

Past attendees have said:

“Thank you to the BIOEMTECH team for the invitation to such an engaging imaging workshop and panel discussion on radioligand theranostics! I thoroughly enjoyed the diverse conversations on topics ranging from dosimetry, imaging modalities, and animal models to their impact on the design of RLTs. I was particularly impressed with the new imaging facility and capabilities.”

Director at AstraZeneca


BIOEMTECH is going above the call of duty by facilitating knowledge sharing within the radiotheranostic community.

Co-Founder & Chief Scientific Officer | Phantech

“The workshop of bioemtech is probably the most important framework in the radioligands innovation. The workshop enables to delve into focal points and challenges in the development practices of innovative radioligands. Sometimes when we want to develop something new we must go all the way back to genesis and this was effectively addressed in Bioemtech workshop.”

Head Drug Developments & Radiopharmaceutical Strategies | Target Pharma

Our Speakers & Panelists



Christine Landlinger - Schubert
VP Preclinical & Transational R&D
OncoOne



Anne Bredenbeck
Senior Scientist
Radiopharmaceutical Technologies
3B Pharmaceuticals



Famke van Renesse - Brouwer
Business to Science Manager
TRACER



Jeff Norenberg
Co-Founder & CEO
iSeek Biopharma



Sujiet Puthenveetil
Director
AstraZeneca



Gareth Smith
Senior Director Research Strategy
Telix Pharmaceuticals




Marion Malenge
Head of *In vivo* Research
ARTBIO



Ada Repetto - Llamazares
Chief Scientific Officer
NucliThera

Our Speakers & Panelists



Satoshi Minoshima

Professor of Radiology and
Imaging sciences
University of Utah



Theoni Assimakopoulos

Senior Regulatory Affairs Manager
Pharmassist



Andreas Goutopoulos

Founder & CEO
Actithera



Jeremy Paull

Chief Scientific & Regulatory Officer
Starpharma



Teodor Yordanov

Chief Scientific Officer
Angios Biotech



Chara Korea

Medical Affairs Manager
Pharmassist



John Koutsikos

President
**Hellenic Society of Nuclear
Medicine & Molecular Imaging**



Mark Konijnenberg

Dosimetry Physicist
Erasmus MC




Syed Nuruddin

Preclinical Research Manager
**Norwegian Medical Cyclotron
Center**

Workshop day 1

Tuesday 30 September



5th Annual

BPW

09:00 Bus transfer from The Golden Age Hotel to BIOEMTECH Laboratories

09:45 - 10:30 Coffee break

Hands-On Session
2,5 hrs (20 minutes per group)

Antonis Skliris

In vitro/Cell lab manager

BIOEMTECH

In vitro assays

Sofia Lagoumtzi

Research Scientist

BIOEMTECH

Model development

Eliza Lambidis

Lead R&D radiochemist

BIOEMTECH

Radio-compound preparation

Argyro Zacharioudaki

Designated veterinarian & *In vivo* research consultant

BIOEMTECH

Anaesthesia preparation

Compound administration

Michalis Asprogerakas

Applications Specialist

BIOEMTECH


Image acquisition

13:00 - 14:30 Lunch and Networking break

15:00 Bus transfer from BIOEMTECH Laboratories to The Golden Age Hotel

Workshop day 2

Wednesday 1 October



5th Annual

BPW

09:00 Registration and welcome coffee

Maria Kitsara

Science & Innovation Manager

BIOEMTECH

09:30

Workshop Opening

All participants

09:50

Participants Roundtable

Oncology Therapies Session

Theodoros Karampelas

Chief Scientific Officer

BIOEMTECH

10:20

From Models to Patients: The Promise of Combining Innovative Therapies with Radioligand Therapy in Cancer Care

Christine Landlinger-Schubert

VP Preclinical & Translational R&D

OncoOne

11:00

Pre-Targ-it® - Radioimmunotherapy with bispecific antibodies for hard-to-treat cancers

11:40 - 12:10 Coffee break

Preclinical tools: models, isotopes & dosimetry Session

Ada Repetto-Llamazares

Chief Scientific Officer

NucliThera

12:10

Animal models to investigate your drug

Teodor Yordanov

Chief Scientific Officer

Angios Biotech

12:50

Non-animal models to investigate your drug

13:30 - 14:30 Lunch and Networking break

Marion Malenge

Head of In vivo Research

ARTBIO

14:30

Exploring the ideal alpha isotope for targeted therapy

Mark Konijnenberg

Dosimetry Physicist

Erasmus MC

15:10

Dosimetry - current status, challenges and translation aspects

Moderator: **Ada Repetto-Llamazares**

Participants: **Marion Malenge, Syed Nuruddin,**

Mark Konijnenberg

15:50


Panel discussion "Alpha emitters and ideal isotopes for therapy"

16:30 - 17:00 Wrap-up & Closing remarks

19:30 Museum visit @ Museum of Cycladic Art

Workshop day 3

Thursday 2 October



5th Annual

BPW

08:30 Registration and welcome coffee

Going to the clinics Session

Famke van Renesse-Brouwer

Business to Science Manager

TRACER

09:00

Phase 0: Fastest In-patients trials
Regulations, execution and possibilities

Theoni Assimakopoulos

Senior Regulatory Affairs Manager

Pharmassist

09:40

Interventional Clinical Trials of
Radiopharmaceutical Products:
Governance, Compliance and
Implementation.

Moderator: **Famke van Renesse-Brouwer**

Participants: **Jeremy Paull, Chara Korea, John**

10:20

Panel discussion "Preparing to go to the
clinic - lessons learned"

Koutsikos

11:00 - 11:30 Coffee break

Preclinical vectors: targets and probes Session

Gareth Smith

Senior Director Research Strategy

Telix Pharmaceuticals

11:30

Current and emerging targets for
radiopharmaceutical therapy

Anne Bredenbeck

Senior Scientist Radiopharmaceuticals Technologies

3B Pharmaceuticals

12:10

Advances in probes for RLT

Moderator: **Theodoros Karampelas**

Participants: **Gareth Smith, Anne Bredenbeck,**

12:50

Panel discussion "Targets and probes in
RLT"

Andreas Goutopoulos

13:30 - 14:30 Lunch and Networking break

Syed Nuruddin

Preclinical Research Manager

Norwegian Medical Cyclotron Center

14:30

Imaging as a guide to RLT development

Sujiet Puthenveetil

Director

AstraZeneca

15:10

Guiding RLT development through ADCs

Moderator: **Sujiet Puthenveetil**

Participants: **Jeff Norenberg, Syed Nuruddin**

15:50

Panel discussion "Guided from
diagnostics to create therapeutics"

16:30 - 17:00 Wrap-up & Closing remarks

20:00 Dinner @ "The Ugly Duckling" traditional restaurant

Workshop day 4

Friday 3 October



09:00 Registration and welcome coffee

Satellite Session

Maria Kitsara

Science & Innovation Manager

BIOEMTECH

09:30

R&D in the RLT field - Ongoing & upcoming EU granted projects

Business of RLT Session

Andreas Goutopoulos

Founder & CEO

Actithera

10:00

New strategies for prolonging tumor retention of radioconjugates - An example from FAP-directed RLT

Jeff Norenberg

Co-founder & CEO

iSeek Biopharma

10:40

Current and practical bottlenecks in RLT development

Jeremy Paull

Chief Scientific & Regulatory Officer

Starpharma

11:20

Leveraging dendrimer technology to enhance radiotheranostic assets: A translational and commercial perspective

12:00 - 12:30 Coffee break

RLT Artificial Intelligence tools Session

Satoshi Minoshima

Professor of Radiology and Imaging sciences

University of Utah

12:30

Clinical AI development and implementation in imaging practice

Moderator: **Satoshi Minoshima**


Participants: **Sujiet Puthenveetil, Jeff Norenberg**

13:10

Panel discussion "Artificial Intelligence adoption"

14:00 Lunch and Closing Ceremony

Our Speakers & Panelists



5th Annual

BPW

- **Jeff Norenberg, Co-Founder & CEO iSeek Biopharma**



Jeff Norenberg, PharmD, PhD, brings over 35 years of experience across academia, industry, and regulatory science to the advancement of molecular imaging and radioligand therapies. As Co-Founder and CEO of iSeek Biopharma, he leads a team focused on developing and delivering innovative diagnostic and therapeutic radiopharmaceuticals to improve patient outcomes.

Throughout his career, Jeff has contributed to first-in-human clinical trials and helped address the regulatory, manufacturing, and supply chain challenges that affect radioligand therapy development. At the University of New Mexico, he served as Director of Radiopharmaceutical Sciences, where he mentored students and conducted research in molecular imaging and radiotherapeutics.

He has co-authored over 150 peer-reviewed publications, holds 12 patents, and is a Fellow of ASHP, APhA, ACNP, and SNMMI. In his keynote, Jeff will explore the current and practical bottlenecks in radioligand therapy development and share ideas for advancing the field together.

- **Marion Malenge, Head of *In vivo* Research ARTBIO**




Marion is a researcher with over a decade of experience in the biotechnology industry, specializing in the development of radiopharmaceuticals for cancer therapy. Currently, she serves as Principal Scientist and Head of In Vivo Research at ARTBIO AS in Norway, where she oversees preclinical research programs, lead multidisciplinary teams and support strategic partnerships. She holds a PhD in Medicine and Health Sciences from the University of Oslo, with a research focus on the preclinical development of radioimmunotherapies. Her previous roles at Oncinvent ASA and Nordic Nanovector ASA involved key scientific contributions across various stages of radiopharmaceutical development.

- **Famke Van Renesse-Brouwer, Business to Science Manager TRACER**



With an educational background in Biomedical Sciences and Business administration, Famke bridges the gap between science and business. After completing her master thesis at the radiopharmacies of GE HealthCare, she continued her career in the radiopharmaceutical field with TRACER as Business to Science manager. TRACER is a dutch clinical research organization (CRO) specializing in first-in-human, phase 0 imaging clinical trials, both for diagnostics and therapeutics. These trials use nuclear and optical molecular imaging techniques to provide critical insights into drug efficiency and enable faster, more accurate decision-making in early drug development. Within TRACER she maintains a broad network of clinical sites and strategic partners across Europe, including contractual negotiations and clinical site start-up. In addition, she coordinates clinical translation from tracer development to GMP implementation of radiopharmaceuticals for FIH studies.

Our Speakers & Panelists



5th Annual

BPW

- **Christine Landlinger-Schubert**, VP Preclinical & Transational R&D **OncoOne**



Christine is VP of Preclinical and Translational R&D at OncoOne, focusing on chronic inflammatory diseases and oncology. Since joining in 2021, she has accelerated preclinical programs toward Phase 1 readiness, drawing on 15 years of experience in drug discovery and non-clinical development in biotech. Previously, she was Director of Lysins at PhagoMed, where she advanced antibacterial drug development and played a key role in the EU EIT Health Goldtrack program, contributing to PhagoMed's acquisition by BioNTech. Before that, she held increasingly senior roles at AFFiRS, leading preclinical development of active immunotherapies. She holds a PhD in Life Sciences, studied microbiology in Vienna and Lund, and served as a postdoctoral fellow at the Institute of Medical Biochemistry and the Children's Cancer Research Institute in Vienna.

- **Sujiet Puthenveetil**, Director **AstraZeneca**



Sujiet Puthenveetil, PhD, is Director at AstraZeneca, where he leads multidisciplinary teams developing next-generation targeted therapies for oncology and other therapeutic areas. He oversees teams of protein engineers, chemists, radiochemists, and bioconjugation scientists, focusing on the advancement of Antibody-Drug Conjugates, Antibody-Oligo Conjugates, and Radioligand Therapies, and has contributed to clinical programs such as AZD9829, AZD0516, and FPI-2068. Previously, he served as Principal Scientist at AbbVie, progressing novel ADCs for autoimmune diseases, including ABBV-154. With over 14 years in the pharmaceutical industry, beginning at Pfizer with a focus on next-generation ADC technologies, he holds a Ph.D. in Chemistry from the University of Utah and completed postdoctoral training in Protein Engineering at MIT.

- **Ada Repetto-Llamazares**, Chief Scientific Officer **NucliThera**




Ada is an expert in innovative R&D for radioligand therapies, with over 15 years of experience in the field. She has contributed to the development of 8 novel radioligand therapies across multiple indications and radionuclide platforms. A published scientist with over 20 peer-reviewed articles, 4 international patents, and numerous conference presentations, she brings deep scientific expertise and strategic leadership.

With more than 10 years as a project director, she has led cross-functional teams through all phases of preclinical R&D, including several projects reaching IND-readiness and up to Phase 2 clinical trials. She also has hands-on experience managing CMC, regulatory, and laboratory operations under GMP/GCLP standards.

As an active contributor to biotech start-up growth, she has helped scale two companies from early-stage teams to fully operational organizations. She is also an experienced leader and mentor, having built high-performing teams and supervised multiple MSc and PhD students through academia-industry collaborations.

Our Speakers & Panelists



5th Annual

BPW

- **Anne Bredenbeck**

Senior Scientist Radiopharmaceutical Technologies **3B Pharmaceuticals**



Anne studied Biology between 1996 and 2001 in Frankfurt and Freiburg, Germany. From 2002 to 2006, she pursued her PhD as a member of the Clinical Research Group “Tumour Immunology” at the Department of Dermatology, Charité – Universitätsmedizin Berlin. She earned her PhD in Tumour Immunology in 2006 from Freie Universität Berlin.

Between 2007 and 2009, she worked as a postdoctoral researcher at Bayer HealthCare, focusing on immunology and dermatology. She then continued at Bayer as a Laboratory Head from 2009 to 2012, leading and coordinating interdisciplinary projects in early preclinical research, particularly in the development of therapies for gynecological indications such as endometriosis and leiomyoma.


Since 2012, she has been working as a (Senior) Scientist at 3B Pharmaceuticals GmbH, where she is responsible for the planning, execution, analysis and monitoring of internal and external in vivo studies. She has extensive experience in in vivo imaging using SPECT/CT and PET/CT and is also accountable for animal husbandry and animal testing operations.

- **Gareth Smith, Senior Director Research Strategy** **Telix Pharmaceuticals**



Gareth Smith has a PhD in Chemistry focusing on radiochemistry from King’s College London. Following his PhD, Gareth worked in R&D at GE Healthcare, developing novel agents for PET and SPECT. Before moving on from GE, his role became more focused on in/out-licensing and asset management which provided a segway into technology transfer with Oxford University Innovation where his work ranged from intellectual property protection through to capital-raising for spin-out companies. Gareth subsequently became COO of Theragnostics Ltd (acquired by Arecium); leading the establishment of radiopharmaceutical supply chains in Europe & US and expanding the company IP portfolio, alongside supporting FDA approval of a diagnostic kit product (Nephroscan®). He then joined ImaginAb where he led a pivot of the company from diagnostic to therapeutic radiopharmaceutical development until the acquisition of the ImaginAb therapy portfolio by Telix in January 2025. Following this acquisition he is Senior Director Research Strategy at Telix.

Our Speakers & Panelists



5th Annual

BPW

- **Mark Konijnenberg**, Dosimetry Physicist **Erasmus MC**



Mark Konijnenberg, PhD, is a physicist specializing in nuclear physics and radiation dosimetry in nuclear medicine. He obtained his Master's degree in Experimental Physics from the University of Amsterdam and completed his PhD at TU Delft, focusing on mesonic exchange currents in neutron capture reactions.

He worked as a postdoctoral researcher at NKI Amsterdam on dosimetry and treatment planning for Boron Neutron Capture Therapy and later as a nuclear medicine dosimetry expert at Mallinckrodt Medical in Petten, the Netherlands. Since 2010, he has been a research physicist at Erasmus MC, focusing on nuclear medicine dosimetry and radiation protection, and developing pre-clinical and clinical dosimetry for targeted radionuclide therapies.

He held a part-time appointment at Radboud UMC in Nijmegen, where he established the Dosimetry Core Unit. He chaired the EANM Dosimetry Committee from 2015–2020 and currently serves on the EANM Radiobiology Task Force and ICRU Report Committee.


- **Teodor Yordanov**, Chief Scientific Officer **Angios Biotech**



Teodor Yordanov holds a PhD in Molecular Cell Biology and Oncology from the Medical University of Innsbruck, Austria, which he completed in 2018. Prior to that, he earned his master's degree in molecular Cell and Developmental Biology (2010–2012) and his bachelor's degree in biology (2006–2009), both from Leopold Franzens University in Innsbruck.

His professional experience includes serving as Chief Scientific Officer (CSO) at Angios FlexCo in Innsbruck since 2024. Before that, he was the Head of Research and Development at the same company from 2022 to 2024. Between 2019 and 2022, he worked as a Postdoctoral Research Fellow at the University of Queensland in Brisbane, Australia. In addition, he held a short-term Visiting Researcher position at Boston University in the United States in 2019. Earlier in his career, he worked as a Scientific Researcher at the Medical University of Innsbruck from 2018 to 2019.

Our Speakers & Panelists



5th Annual

BPW

- **Jeremy Paull**, Chief Scientific & Regulatory Officer **Starpharma**



Jeremy Paull is Chief Scientific and Regulatory Officer at Starpharma, based in Melbourne, Australia. Jeremy has more than 25 years' experience in the biotechnology industry, and leads the development, registration and commercialisation of products to address significant unmet medical needs using Starpharma's proprietary dendrimer, or DEP[®], platform technology. At Starpharma, Jeremy has led the nonclinical and clinical development of dendrimer-based products for oncology, infectious diseases, and women's health applications, leading to the registration and commercialisation of several marketed products. Jeremy currently also leads Starpharma's internal projects and external collaborations on the application of DEP[®] dendrimers to radiopharmaceuticals.

- **Andreas Goutopoulos**, Founder & CEO **Actithera**




Dr. Andreas Goutopoulos founded Actithera with the vision of bringing medicinal chemistry-driven innovation to radioligand therapy. He has over 25 years of experience in drug discovery, including leadership roles at EMD Serono, where he directed the chemistry organization, and at M Ventures, where he served as Entrepreneur-in-Residence supporting company creation and scientific diligence. He has led the discovery of more than a dozen development candidates across therapeutic areas. His scientific leadership and commitment to precision molecular design continue to shape Actithera's approach to building transformative oncology therapeutics.

- **Satoshi Minoshima**, Professor of Radiology and Imaging sciences **University of Utah**



Satoshi Minoshima, MD, PhD, is currently Professor and Anne G. Osborn Chair of Radiology and Imaging Sciences, University of Utah, USA. A global leader in molecular brain imaging, his pioneering work includes imaging characterization of neurodegenerative diseases and worldwide dissemination of statistical mapping software. He has held numerous leadership roles, including President of the SNMMI, Chair of the SNMMI Scientific Program Committee, Chair of the Board of Trustees for the RSNA Research and Education Foundation, and Chair of the RSNA Molecular Imaging Committee. He currently serves as Chair of the SNMMI Value Initiative, Secretary / Treasurer of the Academy for Radiology and Biomedical Imaging Research, and Vice President of the SNMMI Brain Imaging Council. Dr. Minoshima's honors include the Gold Medal of the American Roentgen Ray Society (ARRS); SNMMI Marc Tetalman Memorial Award; Kuhl-Lassen Award; and Henry Wagner Jr. Lecture Award.

Our Speakers & Panelists



5th Annual

BPW

- **Syed Nuruddin**, Preclinical Research Manager **Norwegian Medical Cyclotron Center**



Syed Nuruddin serves as the Preclinical Research Manager at the Norwegian Medical Cyclotron Centre AS, where he collaborates closely with teams in Radiopharmaceutical drug discovery, preclinical research, and business development). In addition to his managerial role, he is affiliated as an Associate Professor-II in the Department of Pharmacy at the University of Oslo.

At Oslo Imaging and Therapy Laboratory (OITL), he oversees a preclinical research facility dedicated to supporting both public and private organizations in their radiopharmaceutical research efforts.

He holds a degree in veterinary medicine and earned his Ph.D. from the Norwegian School of Veterinary Science, focusing on multimodal imaging and the development of novel PET tracers for neurodegenerative disorders. His diverse expertise bridges clinical applications and innovative research in the rapidly evolving field of radiopharmaceuticals.

- **John Koutsikos**, President **Hellenic Society of Nuclear Medicine & Molecular Imaging**




Dr. John Koutsikos, during his post-graduate training acquired expertise in Therapeutics, Neurology and hybrid imaging (PET/CT). Currently he is the Director of Nuclear Medicine Theranostics Center at Henry Dunant Hospital, while till recently he was Director of the Nuclear Medicine Department at 401 General Army Hospital in Athens, Greece.

His clinical practice and research interests are imaging and therapy of thyroid cancer, neuroendocrine tumors and prostate cancer, i.e. Theranostics! Dr. Koutsikos has an extensive range of national and international teaching activities, while he is reviewer in several scientific journals.

Since 2019 he is the President of the Hellenic Society of Nuclear Medicine & Molecular Imaging. His main goal from this position is the extroversion of our Specialty, while his vision is to promote the hybrid imaging (both SPECT/CT and PET/CT) and theranostics. Dr. Koutsikos is his country's delegate to the WFNMB. He is member of the EANM, SNMMI and WARMTH. He is an advisor to the Ministry of Health, participating in various boards including the Working Group of Nuclear Medicine (defining the curriculum of specialty), the Committee on Ionizing Radiation, etc.

Our Speakers & Panelists



5th Annual

BPW

- **Theoni Assimakopoulos**, Senior Regulatory Affairs Manager **Pharmassist**



Senior Manager in Regulatory Affairs with over 15 years of experience in compliance, regulatory strategy, and medical administration. Over the years she progressed from Associate to Senior Manager across leading organizations and multinational firms, consistently delivering expertise in compliance management, regulatory submissions, and cross-functional leadership. She holds a Bachelor of Commerce in Administrative Management from Concordia University, supported by scientific studies (Biology and Health Sciences) at Université de Montréal and Marianopolis College, bringing a unique blend of business insight and analytical precision to regulatory affairs.

- **Chara Korea**, Medical Affairs Manager **Pharmassist**



Dr. Chara Korea began her career in academia, spending a decade conducting research in prestigious institutes across Italy, France, and Greece. Driven by her commitment to advancing applied science innovations, she shifted to the pharmaceutical industry. From 2010 to 2016, she worked at Novartis Vaccines and later at GlaxoSmithKline in Italy, contributing to R&D, clinical development, and global marketing authorization of several well-known bacterial and viral vaccines.

In 2016, she joined Pharmassist Ltd to support the development and commercialization of cutting-edge therapies. In her current role as Medical Affairs Manager, she provides expertise in scientific strategy, clinical research, and regulatory submissions throughout the product lifecycle, from R&D to post-marketing, for drugs, medical devices, and IVDs.

Dr. Korea holds a Ph.D. in Microbiology awarded from the Pasteur Institute and the University Paris VII–Denis Diderot. She is PMP-certified and volunteers with the PMI Greece Chapter.

- **Theodoros Karampelas**, Partner & Chief Scientific Officer **BIOEMTECH**



Biotechnologist by training and holds a PhD in Pharmacology. Since 2009, he has been working on research related with drug discovery and especially in the field of targeted anticancer agents. This allowed him to build critical thinking towards pharmacology as well as a strong bioanalytical background. In addition, during this period, he has established expertise regarding the different methodologies employed in all the stages of preclinical drug discovery in vitro and in vivo. Furthermore, Thodoris has experience in the setting up and maintenance of Quality Systems based on ISO17025 and good laboratory practice (GLP). He joined BIOEMTECH in 2021, where he is now the CSO, responsible for the scientific ground of the preclinical services that are running or planned in BIOEMTECH Laboratories.

How to be part of our Workshop

 **BIOEMTECH**

5th Annual

BPW

BIOEMTECH's Preclinical Workshop

Rates:

- € 900 Early bird (20% discount for registrations before July 4th, 2025)
- €1100 (for registrations after July 4th, 2025)
- €750 Student (requiring student ID)

Registration link at our website

Venue

The Golden Age Hotel of Athens

57 Michalakopoulou str., 11528

Athens, Greece

Hands-On Session will be held at

BIOEMTECH Laboratories

271 Kleisthenous str., 15344,

Gerakas, Greece



**Excited to broaden our
perspectives together
soon in Athens!**